Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
GUANGZIINTERNATIONAL
836892
5
Zhejiang Huayuan Auto Technology
301535
CN Stock MarketDetailed Quotes
688065 Cathay Biotech Inc.
- 52.77
- -0.20-0.38%
Trading Apr 25 10:24 CST
38.06BMarket Cap77.83P/E (TTM)
53.10High52.00Low12.32KlotVolume52.98Open52.97Pre Close64.62MTurnover0.21%Turnover Ratio77.83P/E (Static)721.29MShares56.9852wk High2.18P/B30.78BFloat Cap32.4852wk Low63.56Limit Up583.38MShs Float140.21Historical High42.38Limit Down2.08%Amplitude32.48Historical Low0.19Dividend TTM52.46Avg Price6.16KlotAsk0.36%Div YieldTTM100Lot Size4.86KlotBid
Cathay Biotech Inc. News
Cathay Biotech Inc. (688065.SH): Breakthrough achieved in the molding process of bio-based polyamide continuous fiber composite materials.
On April 22, Gelonghui reported that Cathay Biotech Inc. (688065.SH) stated on the investor interaction platform that the company has made breakthroughs in the forming process of bio-based polyamide continuous fiber composite materials, and has begun to receive commercial Orders in scenarios such as New energy Fund and Logistics. For specific details, please refer to the announcements published by the company on the Shanghai Stock Exchange website.
Cathay Biotech 2024 Profit Up 33%, Revenue Climbs 40%
Kaiser Biotech: 2024 Annual Report Summary
Kaiser Biotech: 2024 Annual Report
2024 ANNUAL REPORT
2024 Annual Report Summary
Cathay Biotech Inc. achieved a revenue exceeding 2.9 billion yuan in 2024, with a 40% growth in core product sales.
① In 2024, Cathay Biotech Inc. achieved record high revenue in recent years, and profitability has resumed its growth trajectory; ② This growth is mainly attributed to the decrease in raw material prices and the decline in fixed costs spread over increased production volume. During the reporting period, the long-chain dicarboxylic acid series generated revenue of 2.67 billion yuan, a year-on-year increase of 39.94%, with a gross margin of 39.71%.
Cathay Biotech Inc. (688065.SH): A cumulative repurchase of 0.22 million shares.
Gelonghui, April 2nd丨Cathay Biotech Inc. (688065.SH) announced that on March 31, 2025, the company repurchased 220,946 shares through the centralized bidding trading system of the Shanghai Stock Exchange, accounting for 0.0306% of the company's total share capital of 721,289,794 shares. The highest transaction price was 45.95 yuan/share, the lowest price was 44.08 yuan/share, and the total amount paid was 9,995,695.95 yuan (excluding stamp duty, transaction commissions, and other trading fees).
Cathay Biotech Completes Filing Process to Issue Shares in Shanghai
Research Reports discovery丨Huaan: Cathay Biotech Inc.’s performance has significantly improved on the margin, maintaining a 'Buy' rating.
Research reports from Huaan highlight that Cathay Biotech Inc. (688065.SH) is expected to achieve a total profit of 0.546 billion yuan in 2024, a year-on-year increase of 21.57%; net income attributable to shareholders is projected to be 0.487 billion yuan, an increase of 32.80% year-on-year, indicating significant marginal improvement in performance and the prominent synergistic effects of the industry chain. The primary reason for growth in 2024 is the recovery in demand for long-chain dicarboxylic acids and the ramp-up of new products for sebacic acid, which will drive high growth in production and sales year-on-year. The company has a clear long-term growth path, and the synergy of technological barriers and policy dividends provides significant long-term advantages. The advantages of the synthetic biology technology platform will release structural dividends driven by Carbon Neutrality goals. In the long term,
Cathay Biotech Inc. (688065.SH): A total of 0.2209 million company shares have been repurchased.
On March 3, Gelonghui reported that Cathay Biotech Inc. (688065.SH) announced that on February 28, 2025, the company repurchased 220,946 shares through the Shanghai Securities Exchange trading system using a centralized bidding trading method, accounting for 0.0379% of the company's total share capital of 583,378,039 shares. The highest transaction price was 45.95 yuan/share, the lowest was 44.08 yuan/share, and the total funds paid amounted to 9,995,695.95 yuan (excluding transaction fees such as stamp tax and trading commissions).
Investing in industry funds + establishing a joint venture, Cathay Biotech Inc. "leverages" Contemporary Amperex Technology and Hefei State Assets.
① Behind Cathay Technology are two major giants, Cathay Biotech Inc. and Contemporary Amperex Technology. ② Cathay Technology mainly engages in the research, production, and sales of products applying Cathay Biotech Inc.'s polyamide composite materials in the fields of power batteries, energy storage, and other New energy areas. ③ The招商凯赛新材料基金 (Zhaoshang Cathay New Materials Fund), co-founded by Cathay Biotech Inc., Hefei State-owned Assets, and China Merchants Shekou Industrial Zone Holdings, was established with a registered capital of 0.65 billion yuan.
Cathay Biotech: 2024 Annual Results Report Announcement
2024 Annual Results Express Announcement
These 4 Measures Indicate That Cathay Biotech (SHSE:688065) Is Using Debt Reasonably Well
Cathay Biotech Inc.'s (SHSE:688065) Share Price Could Signal Some Risk
Cathay Biotech (SHSE:688065) Will Be Hoping To Turn Its Returns On Capital Around
Cathay Biotech Inc. (688065.SH): repurchased 0.0379% of the company's shares.
On January 2, Glonghui reported that Cathay Biotech Inc. (688065.SH) announced that as of December 31, 2024, the company repurchased 220,946 shares of its stock through the centralized bidding trading system of the Shanghai Stock Exchange, accounting for 0.0379% of the company's total share capital of 583,378,039 shares. The highest price of the buyback was 45.95 yuan/share, the lowest price was 44.08 yuan/share, and the total funds paid amounted to 9,995,695.95 yuan (excluding stamp duty, transaction commissions, and other transaction costs).
Cathay Biotech Inc. (688065.SH): plans to jointly invest with entities like Creative Technology to establish a partnership.
On December 16, Longtenghui reported that Cathay Biotech Inc. (688065.SH) announced that in May 2024, it will sign a tripartite strategic cooperation agreement with the Hefei Municipal Government and China Merchants Innovation Technology Group Co., Ltd. (referred to as "China Merchants Innovation Technology"). The parties will fully leverage their respective advantages in industrial policy guidance, application scenario creation, and biomanufacturing technology innovation to build a synthetic biological materials industry cluster. According to the cooperation arrangement in the strategic agreement, to better promote the industrialization of a series of bio-based polyamide composite materials, the three parties will collaborate to establish related entities to engage in the research and development, production of bio-based polyamide composite materials and.
Cathay Biotech Inc. (688065.SH): The company's controlling Shareholder will change from CIB to Shanghai Yao Xiu.
On December 16, Gelonghui reported that Cathay Biotech Inc. (688065.SH) announced that, according to the "Stock Contribution Agreement" signed by its controlling shareholder Cathay Industrial Biotech Ltd. (referred to as "CIB") on June 25, 2023, as part of the overall plan for the issuance of A-shares to specific targets in 2023, CIB intends to transfer its directly held 116,655,640 shares of RMB ordinary A-shares to the Shanghai Yaoqin Biotechnology Partnership (Limited Partnership) (to be established) (subject to final business approval and registration).
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs